Clinical usefulness of serum and immunohistochemical markers in patients with stage Ia and Ic ovarian cancer

Oncology Reports

Volumn 14, Issue 4, 2005, Pages 861-865

  Muramatsu, Toshinari ^a   Mukai, Masaya ^b   Sato, Shinkichi ^b   Tajima, Takayuki ^b   Nagase, Eri ^a   Ikeda, Masae ^a   Goya, Ken Ichi ^a   Shida, Masako ^a   Hirasawa, Takeshi ^a   Murakami, Masaru ^a   Shinozuka, Takao ^c  

^a TOKAI UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY OISO HOSPITAL   (Japan)

^c Department of Gynecology   (Japan)

Author keywords

Early ovarian cancer; Occult neoplastic cell; Prognosis; Tumor marker

Indexed keywords

CA 125 ANTIGEN; CA 19-9 ANTIGEN; KERATIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; BIOSYNTHESIS; BLOOD; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; TIME;

ADULT; AGED; BIOPSY; CA-125 ANTIGEN; CA-19-9 ANTIGEN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644829463     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.4.861     Document Type: Article

References (30)

1. Fiorica JV and Roberts WS: Screening for ovarian cancer. Cancer Control 3: 120-129, 1996. (Pubitemid 26162154)
2. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group Study. J Clin Oncol 21: 3194-3200, 2003. (Pubitemid 46606249)
3. Aabo K, Adam SM, Adnitt P, et al: Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78: 1479-1487, 1998. (Pubitemid 28517545)
4. Trimbos JB, Vergote I, Bolis G, et al: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant Chemotherapy in Ovarian Neoplasm trial. J Natl Cancer Inst 95: 113-125, 2003. (Pubitemid 36193260)
5. Simojoki M, Santala M, Vuopala S and Kauppila A: The prognostic value of peritoneal cytology in ovarian cancer. Eur J Gynaecol Oncol 20: 357-360, 1999.
6. Vergote I, De Brabanter J, Fyles A, et al: Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 357: 176-182, 2001. (Pubitemid 32108089)
7. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Suzuki T, Ino K, Kawai M and Mizutani S: Long-term prognosis of stage I ovarian carcinoma. Prognostic importance of intraoperative rupture. Oncology 65: 29-36, 2003. (Pubitemid 36829088)
8. Fayed ST, Ahmad SM, Kassim SK and Khalifa A: The value of CA125 and CA72-4 in management of patients with epithelial ovarian cancer. Dis Markers 14: 155-160, 1998. (Pubitemid 29324911)
9. Tamakoshi K, Kikkawa F, Shibata K, et al: Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor. Gynecol Oncol 62: 67-72, 1996. (Pubitemid 26234547)
10. Mikami M, Suzuki A, Takehara K, Komiyama S, Ishikawa M and Hirose T: A case of ovarian cancer with remote metastases, with emphasis on changes in tumor marker values. Gynecol Oncol 90: 462-465, 2003. (Pubitemid 36952047)
11. Paulsen T, Marth C, Kaern J, Nustad K, Kristensen GB and Trope C: Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients. Gynecol Oncol 76: 326-330, 2000. (Pubitemid 30131502)
12. Woolas RP, Oram DH, Jeyarajah AR, Bast RC and lacobs II: Ovarian cancer identified through screening with serum markers, but not by pelvic imaging. Int J Gynecol Cancer 9: 497-501, 1999. (Pubitemid 30027555)
13. Gard GB and Houghton CR: An assessment of the value of serum CA 125 measurements in the management of epithelial ovarian carcinoma. Gynecol Oncol 53: 283-289, 1994. (Pubitemid 24187854)
14. Makar AP, Kristensen GB, Bormer OP and Trope CG: Serum CA 125 level allows early identification of nonresponders during induction chemotherapy. Gynecol Oncol 49: 73-79, 1993. (Pubitemid 23148586)
15. Niloff JM, Knapp RC, Lavin PT, et al: The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol 155: 56-60, 1986. (Pubitemid 16100526)
16. Bast RC Jr, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR Jr and Knapp RC: Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol 149: 553-559, 1984. (Pubitemid 14086185)
17. Mukai M, Sato S, Ninomiya H, Kimura T, Komatsu N, Tajima T, Nakasaki H and Makuuchi H: Predicting recurrence and metastasis of Dukes' A primary colorectal cancer with or without proper muscle invasion. Oncol Rep 12: 1305-1308, 2004.
18. Mukai M, Sato S, Kimura T, Ninomiya H, Komatsu N, Tajima T, Nakasaki H and Makuuchi H: Predicting recurrence and metastasis of stage III/Dukes' C colorectal cancer with lymph node metastasis. Oncol Rep 12: 1301-1304, 2004.
19. Mukai M, Sato S, Komatsu N, Kimura T, Ninomiya H, Kawada M, Nakasaki H, Ogoshi K and Makuuchi H: Accuracy of criteria for predicting recurrence and metastasis in stage II and III gastric cancer patients with lymph node metastasis. Oncol Rep 12: 63-66, 2004.
20. Mukai M, Sato S, Kimura T, Komatsu N, Ninomiya H, Nakasaki H, Ogoshi K and Makuuchi H: Criteria for predicting the recurrence and metastasis of stage I and II gastric cancer without lymph node metastasis. Oncol Rep 12: 59-62, 2004.
21. Mukai M, Sato S, Nishida T, Komatsu N, Shiba K, Nakasaki H and Makuuchi H: Selection criteria for high risk and low risk groups of recurrence and metastasis in patients with primary colorectal cancer. Oncol Rep 10: 1753-1758, 2003.
22. Mukai M, Sato S, Komatsu N, Nishida T, Shiba K, Ito I, Nakasaki H and Makuuchi H: Correlation between occult neoplastic cells in the lymph node sinuses and recurrence in patients with Dukes' C colorectal cancer. Oncol Rep 10: 1165-1169, 2003.
23. Nakane PK and Pierce GB: Enzyme-labeled antibodies: preparation and application for localization of tissue antigens. J Histochem Cytochem 14: 929-931, 1966.
24. Nakane PK and Pierce GB: Enzyme-labeled antibody for the light and electron microscopic localization of tissue antigens. J Cell Biol 33: 307-318, 1967.
25. Makar AP, Baekelandt M, Trope CG and Kristensen GB: The prognostic significance of residual disease, FIGO substage, tumor histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol 56: 175-180, 1995.
26. Partridge EE, Gunter BC, Gelder MS, Alvarez RD, Soong SJ, Austin JM and Kilgore LC: The validity and significance of substages of advanced ovarian cancer. Gynecol Oncol 48: 236-241, 1993. (Pubitemid 23075179)
27. Dembo AJ, Davy M, Stenwig AE, Berle EJ, Bush RS and Kjorstad K: Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet Gynecol 75: 263-273, 1990. (Pubitemid 20062245)
28. Shinozuka T, Muramatsu T, Miyamoto, et al: Long-term results and prognostic analysis in advanced and recurrent/refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation. Int J Clin Oncol 4: 273-279, 1999.
29. O'Brien ME, Schofield JB, Tan S, Fryatt I, Fisher C and Wiltshaw E: Clear cell epithelial ovarian cancer (mesonephroid): bad prognosis only in early stages. Gynecol Oncol 49: 250-254, 1993. (Pubitemid 23170001)
30. Mukai M, Sato S, Nakasaki H, et al: Occult neoplastic cells in the lymph node sinuses and recurrence of primary breast, lung, esophageal, and gastric cancer. Oncol Rep 11: 81-84, 2004.